{"entity":{"id":"kcnf1","kind":"target","name":"KCNF1","aka":["potassium voltage-gated channel modifier subfamily F member 1","Voltage-gated potassium channel regulatory subunit KCNF1","Kv5.1","kH1","IK8"],"tldr":"KCNF1 (Voltage-gated potassium channel regulatory subunit KCNF1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","summary":"Regulatory alpha-subunit of the voltage-gated potassium (Kv) channel which, when coassembled with KCNB1 or KCNB2, can modulate their expression and their gating kinetics by acting on deactivation upon repolarisation and inactivation during maintained depolarisation. Accelerates inactivation but has relatively little effect on deactivation. Coexpression with KCNB1 or KCNB2 markedly slows inactivation.\n\nOpen Targets scores its association with cancer at 0.51 (direct and indirect evidence; datatypes literature 0.69, somatic mutation 0.23, clinical 0.76).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:6246","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6246"},{"label":"UniProt Q9H3M0","url":"https://www.uniprot.org/uniprotkb/Q9H3M0/entry"},{"label":"NCBI Gene 3754","url":"https://www.ncbi.nlm.nih.gov/gene/3754"},{"label":"Ensembl ENSG00000162975","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162975"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.76. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"KCNF1","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:6246","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6246","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q9H3M0","url":"https://www.uniprot.org/uniprotkb/Q9H3M0/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000162975","url":"https://platform.opentargets.org/target/ENSG00000162975/associations","note":"association with cancer (MONDO_0004992) 0.51;  (GraphQL API, CC0)"}],"distribution":"one-type","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA group enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA KCNF1: RNA group enriched (brain 45 nTPM, choroid plexus 24 nTPM); high antibody staining in 1 normal tissue. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 1 specific cancer type at or above 0.5 (Lambert-Eaton myasthenic syndrome). (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas KCNF1 tissue","url":"https://www.proteinatlas.org/ENSG00000162975-KCNF1/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000162975 associations","url":"https://platform.opentargets.org/target/ENSG00000162975/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:6246","ensembl":"ENSG00000162975","uniprot":"Q9H3M0","entrez":"3754","firstDescribed":1997,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Su et al, Biochem. Biophys. Res. Commun, 1997, \"Isolation, characterization, and mapping of two human potassium channels\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/9434767/","biology":"Regulatory alpha-subunit of the voltage-gated potassium (Kv) channel which, when coassembled with KCNB1 or KCNB2, can modulate their expression and their gating kinetics by acting on deactivation upon repolarisation and inactivation during maintained depolarisation. Accelerates inactivation but has relatively little effect on deactivation. Coexpression with KCNB1 or KCNB2 markedly slows inactivation. Each modulatory subunit has its own specific properties of regulation, and can lead to extensive inhibitions, to large changes in kinetics, and/or to large shifts in the voltage dependencies of the inactivation process. The gating kinetics depends on the nature and stoichiometry of the associated regulatory sunbunit. Fails to produce a potassium current when expressed alone. Location: Cell membrane (UniProt). Locus 2p25.1 (HGNC).","whereFound":[],"targetClass":"other","prevalence":[]},"route":"/targets/kcnf1/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}]}}